NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$4.8b

Last Updated

2021/05/11 22:30 UTC

Data Sources

Company Financials +

Executive Summary

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. More Details


Snowflake Analysis

Mediocre balance sheet with limited growth.


Similar Companies

Share Price & News

How has Pacific Biosciences of California's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PACB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: PACB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-5.4%

PACB

-3.0%

US Life Sciences

-1.2%

US Market


1 Year Return

584.4%

PACB

47.0%

US Life Sciences

48.3%

US Market

Return vs Industry: PACB exceeded the US Life Sciences industry which returned 47% over the past year.

Return vs Market: PACB exceeded the US Market which returned 48.3% over the past year.


Shareholder returns

PACBIndustryMarket
7 Day-5.4%-3.0%-1.2%
30 Day-25.1%-2.6%0.2%
90 Day-47.5%-4.8%1.6%
1 Year584.4%584.4%47.2%47.0%50.8%48.3%
3 Year875.3%875.3%104.3%103.2%62.0%51.9%
5 Year168.3%168.3%210.0%206.3%126.9%101.7%

Long-Term Price Volatility Vs. Market

How volatile is Pacific Biosciences of California's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pacific Biosciences of California undervalued compared to its fair value and its price relative to the market?

17.03x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PACB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PACB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PACB is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: PACB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PACB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PACB is overvalued based on its PB Ratio (17x) compared to the US Life Sciences industry average (7.1x).


Future Growth

How is Pacific Biosciences of California forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-13.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PACB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PACB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PACB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PACB's revenue (30.9% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: PACB's revenue (30.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PACB is forecast to be unprofitable in 3 years.


Past Performance

How has Pacific Biosciences of California performed over the past 5 years?

3.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PACB is currently unprofitable.

Growing Profit Margin: PACB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PACB is unprofitable, but has reduced losses over the past 5 years at a rate of 3.7% per year.

Accelerating Growth: Unable to compare PACB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PACB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (17.4%).


Return on Equity

High ROE: PACB has a negative Return on Equity (-21.13%), as it is currently unprofitable.


Financial Health

How is Pacific Biosciences of California's financial position?


Financial Position Analysis

Short Term Liabilities: PACB's short term assets ($1.2B) exceed its short term liabilities ($33.7M).

Long Term Liabilities: PACB's short term assets ($1.2B) exceed its long term liabilities ($938.6M).


Debt to Equity History and Analysis

Debt Level: PACB's debt to equity ratio (319.3%) is considered high.

Reducing Debt: PACB's debt to equity ratio has increased from 17.1% to 319.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PACB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PACB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Pacific Biosciences of California current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PACB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PACB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PACB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PACB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PACB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Christian Henry (52 yo)

0.67

Tenure

US$100,333

Compensation

Mr. Christian O. Henry, MBA, serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He has been President and Chief Executive Officer at Pacific Biosciences of California, Inc. S...


Leadership Team

Experienced Management: PACB's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: PACB's board of directors are seasoned and experienced ( 10.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PACB insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.8%.


Top Shareholders

Company Information

Pacific Biosciences of California, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pacific Biosciences of California, Inc.
  • Ticker: PACB
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.779b
  • Shares outstanding: 198.37m
  • Website: https://www.pacb.com

Number of Employees


Location

  • Pacific Biosciences of California, Inc.
  • 1305 O’Brien Drive
  • Menlo Park
  • California
  • 94025
  • United States

Listings


Biography

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio’s Systems, which conduct, monitor, and an...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/11 22:30
End of Day Share Price2021/05/11 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.